Sai Life Sciences Q1FY26 Revenue Rises 77 Per Cent YoY

08 Aug 2025 CW Team

Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.

Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.

Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.

Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.

To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.

Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”

CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”

Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO), reported strong financial results for the first quarter of fiscal year 2026, led by significant growth in its CDMO segment.Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Infrastructure Urban

30 May 2026

Panasonic Showcases Connected Display Solutions

Panasonic Life Solutions India showcased its integrated display, projection, broadcast and communication technologies at Panasonic Tech Summit 2026 in New Delhi. Hosted through its System Solutions Division, the two-day event highlighted connected technology solutions for education, healthcare, retail, transportation, corporate offices and entertainment.The summit, themed ‘Turning Technology into Value’, featured experience-led zones covering QSR, retail, transit, corporate offices, healthcare, education, security, projection, home theatre and professional displays. Panasonic also introduc..

Infrastructure Transport

30 May 2026

Kapsch to Deliver India’s First C-ITS Project

"Kapsch TrafficCom will deliver India’s first Cooperative Intelligent Transport Systems project on a key expressway near New Delhi. The project will be implemented with Superwave Communication And Infrasolution Limited to demonstrate how connected mobility can improve road safety and traffic efficiency.The pilot will use real-time connectivity and AI-enabled situational awareness to support road users, especially in high-risk areas such as temporary work zones. Drivers will receive alerts on roadworks, maintenance vehicles, hazardous locations, traffic queues and temporary virtual signage di..

Infrastructure Urban

30 May 2026

Eurobond Net Profit Rises 44 Per Cent

Euro Panel Products, the parent company of Eurobond, reported a 44.13 per cent year-on-year rise in net profit for FY25–26. The company’s revenue from operations grew 18.91 per cent to Rs 503.20 crore, compared to Rs 423.18 crore in the previous financial year.The company’s full-year EBITDA stood at Rs 56.67 crore, marking a 31.82 per cent increase. Profit after tax rose to Rs 26.56 crore, while net worth increased 20.15 per cent to Rs 160.07 crore. Earnings per share for the year stood at Rs 10.84.Divyam Rajesh Shah, Whole Time Director and CFO, Euro Panel Products, said the company’s..